BioCote® technology proven effective against a 4th multi-drug resistant “superbug”

In Armstrong Medical Ltd’s efforts to reduce the risks associated with hospital acquired infections, AquaVENT® heated breathing circuits are supplied.

15th April 2013

In Armstrong Medical Ltd’s efforts to reduce the risks associated with hospital acquired infections, AquaVENT® heated breathing circuits are supplied with BioCote® antimicrobial additive to limit the spread of bacterium species between patients and users, should transferable bacteria come into contact with the surfaces of the breathing circuit.

BioCote® technology in AquaVENT® heated breathing circuits uses inorganic silver ion particles dispersed homogenously throughout the polymer used to form components of the breathing circuit.

On the 9th April 2013 our manufacturing partner BioCote® issued a press release (please click here for a link to the full press release) stating they had commissioned testing of their antimicrobial technology against a carbapenem-resistant Enterobacteria (CRE).

Their independently-performed ISO 22196 test demonstrated elimination of over 99.9% of the bacterium Klebsiella pneumoniae.

BioCote® stated that their technology has already been proven to be effective against a wide range of bacteria and fungi and this brings the total number of multi-drug resistant bacteria which BioCote® technology is known to be effective against to four:

  1. MRSA (Methicillin-resistant Staphylococcus aureus)
  2. VRE (Vancomycin-resistant Enterococcus)
  3. ESBL (Extended Spectrum Beta Lactamase producing E. coli)
  4. CRE (Carbapenem-resistant Enterobacteriaceae, Klebsiella pneumoniae)

For further information about the diverse range of products that Armstrong Medical Ltd sell please contact Armstrong Medical’s Customer Service team on +44 (0) 28 7035 6029 (Phone lines are open Monday to Friday 9am to 5pm GMT) or email us info@armstrongmedical.net. Alternatively you can visit the BioCote® website for more information.